首页> 外文期刊>Colorectal disease : >How can we operate safely in the setting of immunosuppression? Sims et al.
【24h】

How can we operate safely in the setting of immunosuppression? Sims et al.

机译:我们如何操作设置的安全吗

获取原文
获取原文并翻译 | 示例
           

摘要

While the effect of immunosuppressive therapy on postoperative outcomes have been thoroughly evaluated in patients with inflammatory bowel disease, there are less outcome data in immunosuppressed patients undergoing surgery for colorectal cancer. Sims et al. [1] utilized the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database to determine the effect of immunosuppression on 30-day postoperative morbidity and mortality following surgery for colon and rectal cancer. As one might expect, the authors found an increased rate of 30-day postoperative morbidity and mortality in the group receiving immunosuppression. While this is useful information and captures a large number of patients, there are important limitations to the ACS-NSQIP database.
机译:虽然免疫抑制治疗的效果术后结果已经彻底评估患者的炎症性肠疾病,有更少的结果数据免疫抑制患者接受手术结直肠癌。美国国家的外科医生质量改进计划(ACS-NSQIP)数据库确定免疫抑制的影响30天的术后发病率和死亡率手术后对结肠癌和直肠癌。有人可能认为,作者发现了一个增加30天术后发病率和死亡率在接收免疫抑制。信息和捕捉大量的病人,有重要的局限性ACS-NSQIP数据库。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号